|
|
|
| Exploration of a new hybrid design sequence in drug interchangeability |
| LING Jia1 LIU Shengjie2 YAN Fangrong2▲ |
1.College of Education, Jiangsu Open University, Jiangsu Province, Nanjing 210019, China;
2.College of Science, China Pharmaceutical University, Jiangsu Province, Nanjing 210009, China |
|
|
|
Abstract Objective To propose a new hybrid design sequence (TTRR, RRTT, RTTR, TRRT) to explore its application in drug interchangeability. Methods Based on criterion for drug interchangeability (SCDI) scaled by Chow, etc. as evaluation criteria, the application of the new sequence in drug interchangeability was explored by considering the variation among drug individuals, and was compared with the common sequence (TRTR, RTRT). Results Through computer simulation of different situations, it was found that the new sequence presented a consistent trend. In addition, the new sequence presented in this study was more sensitive than the common sequence when the key parts σWR, σD of drug interchangeability were changed. Conclusion Although the new sequences are more sensitive to variation than the common sequence in drug interchangeability, the additional two sequences make it less effective in sample size.
|
|
|
|
|
|
[1] 朱赛楠，马林茂.生物利用度—生物等效性评价方法概述[J].中国临床药理学杂志，2003，19（5）：388-392.
[2] 张天一.仿制药一致性评价工作全面展开[N].中国医药报，2016-05-30（001）.
[3] 凌佳，盛海林.基于统计模型的平均生物等效性检验[J].统计与决策，2013，13（2）：8-11.
[4] 刘华.3×3设计中个体生物等效性评价的广义P-值法[J].阜阳师范学院学报，2005，22（4）：20-23.
[5] 张孔生，葛莉.基于自助法和随机加权法的个体生物等效性评价[J].阜阳师范学院学报，2008，25（2）：7-11.
[6] 李玲玲，都丽萍，张钰宣，等.仿制药与原研药间可互换性探讨[J].中国药学杂志，2015，50（2）：178-181.
[7] 谢松梅，高晨燕，白玉，等.生物类似药临床相似性比较试验设计和评价的思考[J].中国药学杂志，2015，50（6）：490-493.
[8] FDA. Guidance for Industry，Statistical Approaches to Establishing Bioequivalence [D]. U.S.Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research（CDER），2001.
[9] Chow SC，Shao J，Wang H. Individual bioequivalence testing under 2x3 designs [J]. Stat Med，2002，21（5）： 629-648.
[10] Chow SC，Liu J. Design and Analysis of Bioavailability and Bioequivalence Studies，Third Edition [M]. New York： CRC Press，2008：1-10.
[11] Chen M，Patnaik R，Hauck WW，et al. An individual bioequivalence criterion：Regulatory considerations [J]. Stat Med，2000，19（20）：2821-2842.
[12] Chow SC，Xu HL，Endrenyi L，Song F Y. A new scaled criterion for drug interchangeability [J]. Chinese J Pharm Anal，2015，35（5）：844-848.
[13] Chen M，Chow SC. Assessing bioequivalence and drug interchangeability [J]. J Biopharma Stat，2017，27（2）： 272-281.
[14] Endrenyi L，Taback N，Tothfalusi L. Properties of the estimated variance component for subject-by-formulation interaction in studies of individual bioequivalence [J]. Stat Med，2000，19（20）：2867-2878.
[15] Benet L. Bioavailability and bioequivalence：definitions and difficulties in acceptance criteria. In：Midha KK，Blume HH，editors. Bio-International 2：bioavailability，bioequivalence and pharmacokinetics [C]. Stuttgart：Medpharm，1993：27-35.
[16] European Medicines Agency [EMEA] Committee for Medicinal Products for Human Use [CHMP]. Note for guidance on the investigation of bioavailability and bioequivalence [R]. London：EMEA，2001：1-22.
[17] Boddy AW，Snikeris FC，Kringle RO，et al. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs [J]. Pharm Res，1995，12（12）：1865-1868.
[18] 何春远，孙华，谢海棠.高变异药物生物等效性试验及量化评价[J].中国临床药理学与治疗学，2016，21（7）：721-730.
[19] 李自强，黄宇虹，王保和，等.FDA，EMA和CFDA关于高变异性药物生物等效性研究指南比较[J].中国新药杂志，2017，26（1）：7-13.
[20] 言方荣，朱惠红，蒋丽芸，等.生物等效性评价早期停止条件研究[J].中国卫生统计，2017，34（5），825-828， 831.
[21] 刘月，蔡晶晶，于宣宣，等.高变异药物生物等效性分析方法的比较[J].中国临床药理学与治疗学，2019，24（7）， 792-798.
[22] 赵杨，于浩，娄冬华，等.交叉设计多中心临床试验的混合效应模型[J].中国临床药理学与治疗学，2005，10（1）：116-120.
[23] Tothfalusi L，Endrenyi L. An exact procedure for the evaluation of reference-scaled average bioequivalence [J]. AAPS J，2016，18（2）：476-489.
[24] Karalis V，Macheras P. An insight into the properties of a two-stage design in bioequivalence studies [J]. Pharm Res，2013，30（7）：1824-1835. |
|
|
|
